NAMS Stock Analysis: Buy, Sell, or Hold?
NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares
$36.99
2.09 (5.99%)
▲
5d:
+9.21%
30d:
+13.22%
90d:
+8.41%
HOLD
MODERATE Confidence
Analysis Updated: Jul 7, 2026 12:00 AM ET
Earnings: Aug 05, 2026
27d
Smart Money Distribution
None View Scanner →
Strength: 6.4/10
Get Alerted When NAMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called NAMS this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD - EXTENDED: NAMS is 8.1% above its trading range ($34.22). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
📊 HOLD - EXTENDED: NAMS is 8.1% above its trading range ($34.22). Fundamentals are solid but entry is stretched. Hold existing positions; wait for pullback to add new shares.
In-depth Analysis How we analyze
Valuation Analysis: NAMS is currently trading at $36.99, which is considered slightly high relative to its 30-day fair value range of $30.25 to $34.22.
Technical Outlook: Technically, NAMS is showing sideways momentum. The price is approaching resistance at $36.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: NAMS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.68 (+34.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NAMS is showing sideways momentum. The price is approaching resistance at $36.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 6.0% recently.
Market Sentiment: NAMS has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $49.68 (+34.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$30.25 -
$34.22
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.2%
Protect Your Profits
Holding NAMS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+6.0%)
- BULLISH: Trading 34.3% below Wall St target ($49.68)
- CAUTION: Extended 8.1% above its trading range - wait for pullback
Trading Range Analysis
30-Day Trading Range
$30.25 -
$34.22
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$30.31
Resistance Level
$36.34
Current Trend
Sideways
Technical data as of
Jul 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-28.04
Wall Street Target
$49.68
(+34.3%)
Revenue Growth (YoY)
2.1%
Share & Embed Analysis
Last updated: July 07, 2026 9:14 PM ET
Data refreshes hourly during market hours. Next update: 10:14 PM
Data refreshes hourly during market hours. Next update: 10:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
14
Sells
Net
INSIDERS SELLING
Recent Transactions
Louis G Lange
SELL
44619 shares
2026-03-11
Johannes Jacob Piete Kas…
SELL
101409 shares
2026-03-09
Johannes Jacob Piete Kas…
SELL
94124 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$276 | 64 BUY |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$57 | 53 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$293 | 59 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$46 | 65 BUY |
Advanced NAMS Option Strategies
Professional options setups generated by AI based on today's NAMS price and gamma walls.